MeiraGTx to Present at the Barclays Gene Editing & Gene Therapy Summit

Rhea-AI Summary

MeiraGTx Holdings, a clinical stage gene therapy company, announced that Alexandria Forbes, Ph.D., CEO, will present at the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020, at 1:30 p.m. ET. The event can be accessed via a live webcast on the company's investors page. MeiraGTx has a robust pipeline with six clinical programs focusing on unmet medical needs in inherited retinal diseases, neurodegenerative diseases, and severe xerostomia. The company aims to advance innovative gene therapy treatments for these serious health conditions.

LONDON and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barclays Gene Editing & Gene Therapy Summit on Monday, November 16, 2020 at 1:30 p.m. ET.

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.meiragtx.com. A replay of the webcast will be available for approximately 30 days following the presentation.

About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit www.meiragtx.com.

Contacts

Investors:
MeiraGTx
Elizabeth (Broder) Anderson
(646) 860-7983
elizabeth@meiragtx.com

or

Media:
W2O pure
Christiana Pascale
(212) 257-6722
cpascale@purecommunications.com

FAQ

What is the date and time of MeiraGTx's presentation at the Barclays Summit?

MeiraGTx will present at the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020, at 1:30 p.m. ET.

Where can I watch the MeiraGTx presentation live?

The live webcast of the presentation can be viewed on the Investors page of MeiraGTx's website.

What are the main areas MeiraGTx is focusing on with its gene therapies?

MeiraGTx is focused on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia.

How many clinical programs does MeiraGTx currently have?

MeiraGTx has six programs currently in clinical development.

What is the stock symbol for MeiraGTx?

The stock symbol for MeiraGTx is MGTX.